Filing Flows › Health Care › ENvue Medical (FEED)
ENvue Medical (FEED) earnings and revenue breakdown
Latest: Q2 2026 · 10-Q filed Aug 17, 2026 · ENvue Medical (FEED) Q2 2026 earnings results →
Q2 2026 Revenue down 52% year over year to $239K
ENvue Medical made $239K in Q2 2026 (-52% Y/Y): ENvue $184K, Nano Vibronix $55K. Operating margin n/m, net loss $4.9M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Aug 17, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $239K in Q2 2026, down 52% year over year and down 63% from the previous quarter. ENvue was the largest line at 77% of revenue. Nano Vibronix lost $390K year over year (down 88%), 153% of the total change.
Operating costs exceeded revenue by $5.5M, an operating margin of -2290.4%. Total costs grew 28% against a revenue fall of 52%. The fastest-growing cost line was Sales & marketing (+78%). The quarter ended with a net loss of $4.9M, wider than the previous quarter's $3.8M loss.
Operating cash flow was −$2.7M. Non-cash charges added back $219K of depreciation and amortization. Working capital and other items added $2.0M. Capital expenditures of $27K exceeded it, leaving free cash flow of −$2.7M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 10-Q | Aug 17, 2026 | $239K | -52% | n/m | −$4.9M | −$2.7M |
| Q1 2026 | 10-Q | May 18, 2026 | $653K | -36% | -568.3% | −$3.8M | −$4.3M |
| Q4 2025 | 10-K | Apr 15, 2026 | $312K | -30% | n/m | −$12.9M | −$2.7M |
| Q3 2025 | 10-Q | Nov 14, 2025 | $722K | +92% | -311.2% | $510K | −$2.0M |
| Q2 2025 | 10-Q | Aug 19, 2025 | $494K | -40% | -804.9% | −$4.0M | −$3.4M |
| Q1 2025 | 10-Q | May 20, 2025 | $1.0M | +11% | -180.7% | −$2.5M | −$1.3M |
| Q4 2024 | 10-K | Mar 31, 2025 | $444K | -62% | -308.6% | −$1.4M | −$548K |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
Customers and suppliers named in filings
Buys from
About ENvue Medical
ENvue Medical, Inc. (the “Company”), formerly known as NanoVibronix, Inc., was incorporated as a Delaware corporation in October 2003. In December 2025, the Company changed its name from NanoVibronix, Inc. to ENvue Medical, Inc. Prior to such a name change, on February 14, 2025, the Company consummated and completed its merger (the “Merger”) pursuant to the Agreement and Plan of Merger, dated as of February 14, 2025 (the “Merger Agreement”), as further described herein. Following the consummation of the Merger, the Company conducts its operations through two wholly-owned subsidiaries: (i) NanoVibronix Ltd.
In its own words, from its 10-K, filed Apr 15, 2026.
ENvue Medical against its Orthopedic, Prosthetic & Surgical Appliances & Supplies peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: -52% against the peers' median +9%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| FEED ENvue Medical | Q2 2026 | $239K | -52% | n/m |
| ISRG Intuitive Surgical | Q3 2026 | $3.0B | +22% | 19.4% |
| ZBH Zimmer Biomet Holdings | Q3 2026 | $2.1B | +3% | 14.9% |
| EW Edwards Lifesciences | Q3 2026 | $1.7B | +10% | 17.4% |
| STE Steris | Q2 FY27 | $1.6B | +9% | 18.5% |
| ALGN Align Technology | Q3 2026 | $1.0B | +2% | 16.7% |
| ENOV Enovis | Q3 2026 | $559M | +2% | 0.6% |
| MSA MSA Safety | Q3 2026 | $536M | +14% | 16.4% |
| CDRE Cadre Holdings | Q3 2026 | $203M | +30% | 14.0% |
Source: ENvue Medical 10-Q on SEC EDGAR · CIK 1326706 · Orthopedic, Prosthetic & Surgical Appliances & Supplies
More on FEED
History
Every quarter: Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results · Q4 2024 results